Lipika Goyal
利皮卡·戈亚尔
MD, MPhil
Associate Professor of Medicine; Director, Cholangiocarcinoma Program医学副教授；胆管癌项目主任
👥Biography 个人简介
Lipika Goyal, MD, MPhil is Associate Professor of Medicine at Harvard Medical School and MGH, where she directs the Cholangiocarcinoma Program. She is a leading precision oncology researcher focused on IDH1/IDH2 and FGFR2 alterations in cholangiocarcinoma, and has pioneered the use of ctDNA and liquid biopsy to track resistance mechanisms and guide treatment in biliary tract cancers.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
IDH1/IDH2 Precision Oncology in Cholangiocarcinoma
Led clinical and translational studies defining the landscape of IDH1/IDH2 mutations in cholangiocarcinoma and evaluating targeted inhibitors, contributing to approval of ivosidenib and expanding understanding of IDH-driven oncogenesis.
ctDNA and Liquid Biopsy in Biliary Tract Cancer
Pioneered use of circulating tumor DNA to characterize acquired resistance to FGFR2 and IDH1 inhibitors in cholangiocarcinoma, informing sequential treatment strategies and next-generation trial design.
Representative Works 代表性著作
Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma
Cancer Discovery (2017)
Landmark study identifying polyclonal FGFR2 kinase domain resistance mutations via ctDNA in cholangiocarcinoma patients progressing on FGFR inhibitors, defining the molecular basis of acquired resistance.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 利皮卡·戈亚尔 的研究动态
Follow Lipika Goyal's research updates
留下邮箱，当我们发布与 Lipika Goyal（Massachusetts General Hospital / Harvard Medical School）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment